What is SynVaccine?
Based in Tel Aviv, Israel, SynVaccine operates at the intersection of computational biology and advanced therapeutics. The company specializes in the rational design and construction of viral-based products, leveraging its proprietary SynRAD platform to address complex challenges in gene therapy, cancer immunotherapy, and infectious disease management. By integrating sophisticated engineering principles with biological systems, SynVaccine provides critical solutions for healthcare providers and researchers, effectively bridging the gap between theoretical immunology and clinical application. Its focus on oncolytic viruses and phage therapy positions the firm as a significant player in the next generation of precision medicine.
How much funding has SynVaccine raised?
SynVaccine has raised a total of $1.7M across 1 funding round:
Private Equity
$1.7M
Private Equity (2017): $1.7M, investors not publicly disclosed
Key Investors in SynVaccine
Undisclosed Investor
An institutional capital partner focused on long-term growth and strategic scaling within the high-tech biotechnology sector.
What's next for SynVaccine?
Following this major enterprise-level funding, SynVaccine is expected to scale its operational capacity and expand the utility of the SynRAD platform. The strategic allocation of this capital will likely prioritize the advancement of its pipeline toward clinical trials and the strengthening of its intellectual property portfolio. As the company transitions into a more mature phase of development, the focus will shift toward commercializing its viral engineering solutions and forging deeper partnerships within the global biotechnology sector. This growth phase is critical for validating the scalability of its computational design model in real-world medical environments.
See full SynVaccine company page
